Profund Advisors
SGMT icon

Profund Advisors’s Sagimet Biosciences SGMT Stock Holding History

Profund Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$195K Buy
19,737
+5,234
+36% +$48.1K 0.01% 1024
2026
Q2 		$112K Buy
+14,503
New +$98.6K ﹤0.01% 1143

Other funds holding SGMT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Profund Advisors's SGMT Position: Q3 2026 in Review

Profund Advisors increased its Sagimet Biosciences (SGMT) stake by 36% in Q3 2026, buying an estimated $48.1K and bringing the position to 19,737 shares worth $195K. The position accounts for 0.01% of the portfolio, ranked #1024.

Profund Advisors first reported a position in SGMT in Q2 2026 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

  • Profund Advisors held 19,737 shares of Sagimet Biosciences worth $195K as of Q3 2026.
  • Profund Advisors bought 5,234 Sagimet Biosciences shares in Q3 2026, an estimated $48.1K.
  • Sagimet Biosciences made up 0.01% of Profund Advisors's portfolio in Q3 2026, its #1024 holding.
  • Profund Advisors first reported a position in Sagimet Biosciences in Q2 2026 and has held it in 2 quarters since.
  • 48 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.